Key result
Cryoballoon ablation for AF yields similar arrhythmia recurrence rates in normal weight and overweight patients.
Why the study?
Obesity is an important risk factor for AF development, but data on cryoballoon ablation outcomes in obese patients have been scarce.
Does cryoballoon ablation have similar efficacy and safety in obese compared to non-obese patients with atrial fibrillation?
Meta-Analysis
Does cryoballoon ablation have similar efficacy and safety in obese compared to non-obese patients with atrial fibrillation?
Effect estimate: RR 0.95 (95% CI 0.82-1.11)
p-value: p=0.55
Cryoballoon ablation is equally effective and safe for atrial fibrillation in obese patients compared to non-obese patients, though it involves increased radiation exposure.
Supports cryoballoon ablation in overweight AF patients; confirms comparable efficacy across BMI categories.
Introduction: Obesity is an important risk factor for atrial fibrillation (AF) development. Data on cryoballoon ablation (CBA) outcomes in obese patients have so far been scarce. We reviewed the existing literature to compare the efficacy and safety of CBA in obese versus non-obese AF patients. Methods: A systematic literature search was conducted for studies comparing clinical outcomes (arrhythmia recurrence and/or procedural data and/or safety outcomes) between obese and non-obese patients undergoing CBA for AF. Statistical pooling was performed according to a random-effects model with generic inverse-variance weighting of relative risks (RRs) and standardised mean differences (SMDs) computing risk estimates with 95% confidence intervals (CIs). Results: Obese and non-obese patients had comparable arrhythmia recurrence rates (normal versus overweight, RR = 0.95, 95% CI: 0.82–1.11, p = 0.55, I2% = 91%; normal versus class I obesity, RR = 0.97, 95% CI: 0.82–1.13, p = 0.68, I2% = 87%; normal versus class II obesity, RR = 0.98, 95% CI: 0.91–1.07, p = 0.29, I2% = 65%). Procedure time was marginally increased in obese patients compared to non-obese counterparts (normal versus overweight, SMD = 0.05, 95% CI: −0.15–0.26, p = 0.62, I2% = 74%; normal versus class I obesity, SMD = 0.10, 95% CI: −0.00–0.19, p = 0.06, I2% = 2%; overweight versus class I obesity, SMD = 0.11, 95% CI: 0.01–0.21, p = 0.048, I2% = 25%). Regarding radiation exposure, fluoroscopy time was increased in patients with class I obesity compared to normal-weight or overweight patients and dose area product was also increased in obese patients compared to non-obese patients. Lastly, the risk of complications did not differ between obese and non-obese patients. Statistical heterogeneity and the small number of patients included are the main limitations of this study. Conclusion: CBA seems to be effective for obese patients suffering from AF, featuring also similar safety outcomes with non-obese individuals. Radiation exposure was increased in obese patients.
No takes yet. Share an insight, caveat, or question.
Vrachatis et al. (2025) conducted a meta-analysis in Atrial fibrillation. Cryoballoon ablation vs. Non-obese patients was evaluated on Arrhythmia recurrence (normal versus overweight) (RR 0.95, 95% CI 0.82-1.11, p=0.55). Cryoballoon ablation for atrial fibrillation showed comparable arrhythmia recurrence rates between normal weight and overweight patients (RR 0.95; 95% CI 0.82-1.11; p=0.55).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: